, Volume 41, Issue 3, pp 669–673 | Cite as

Ciprofloxacin reduces the risk of hemolytic uremic syndrome in patients with Escherichia coli O104:H4-associated diarrhea

  • H. F. Geerdes-Fenge
  • M. Löbermann
  • M. Nürnberg
  • C. Fritzsche
  • S. Koball
  • J. Henschel
  • R. Höhn
  • H. C. Schober
  • S. Mitzner
  • A. Podbielski
  • E. C. Reisinger
Brief Report



Whether antibiotic treatment in patients with enterohemorrhagic Escherichia coli (EHEC)-associated diarrhea influences the risk of hemolytic uremic syndrome (HUS) has still to be elucidated.

Patients and methods

During the EHEC epidemic which occurred in northern Germany in spring 2011, 24 patients with E. coli O104:H4 infection were treated at our hospitals, 19 of whom developed HUS. The use of antibiotics before and after the onset of HUS was documented, and the outcome in patients with and without antibiotic treatment was evaluated.


Of the 24 patients with EHEC-associated diarrhea, seven received antibiotics before any signs of HUS were present (ciprofloxacin, cefotaxime, amoxicillin and/or metronidazole). Four of these seven patients (57 %) and 15 of the 17 patients (88 %) who were treated without antibiotics developed HUS (p = 0.12). Microbiological testing showed all E. coli O104:H4 to be extended-spectrum beta lactamase producers and thus susceptible only to fluoroquinolones, aminoglycosides and carbapenems. Two of the five patients (40 %) treated with ciprofloxacin and 17 of the 19 patients (89 %) treated without ciprofloxacin developed HUS (p = 0.043).


In our E. coli O104:H4-infected patients, treatment of diarrhea with antibiotics did not increase the risk of HUS. Significantly fewer patients treated with ciprofloxacin developed HUS than patients who did not receive ciprofloxacin.


Metronidazole Fluoroquinolones Azithromycin Hemolytic Uremic Syndrome Eculizumab 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Conflict of interest



  1. 1.
    Frank C, Werber D, Cramer JP, et al. Epidemic profile of Shiga-toxin–producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med. 2011;365:1771–80.PubMedCrossRefGoogle Scholar
  2. 2.
    Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000;342:1930–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Safdar N, Said A, Gangnon RE, Maki DG. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis. A meta-analysis. JAMA. 2002;288:996–1001.PubMedCrossRefGoogle Scholar
  4. 4.
    Phillips B, Tyerman K, Whiteley SM. Use of antibiotics in suspected haemolytic-uraemic syndrome—evidence based case report. Br Med J. 2005;330:409–10.CrossRefGoogle Scholar
  5. 5.
    Panos GZ, Betsi GI, Falagas ME. Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection? Aliment Pharmacol Ther. 2006;24:731–42.PubMedCrossRefGoogle Scholar
  6. 6.
    Robert Koch Institute (RKI). Available at:
  7. 7.
    Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 21st informational supplement. Approved standard CLSI document M100-S21. CLSI, Wayne, 2011.Google Scholar
  8. 8.
    Menne J, Nitschke M, Stingele R, et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. Br Med J. 2012;345:e4565.CrossRefGoogle Scholar
  9. 9.
    Rosales A, Hofer J, Zimmerhackl LB, et al. Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis. 2012;54:1413–21.PubMedCrossRefGoogle Scholar
  10. 10.
    Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR, Watkins SL, Tarr PI. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis. 2012;55:33–41.PubMedCrossRefGoogle Scholar
  11. 11.
    Smith KE, Wilker PR, Reiter PL, Hedican EB, Bender JB, Hedberg CW. Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota. Pediatr Infect Dis J. 2012;31:37–41.PubMedCrossRefGoogle Scholar
  12. 12.
    Walterspiel JN, Ashkenazi S, Morrow AL, Cleary TG. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I. Infection. 1992;20:25–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Bielaszewska M, Idelevich EA, Zhang W, Bauwens A, Schaumburg F, Mellmann A, Peters G, Karch H. Epidemic Escherichia coli O104:H4: effects of antibiotics on Shiga toxin 2 production and bacteriophage induction. Antimicrob Agents Chemother. 2012;56:3277–82.PubMedCrossRefGoogle Scholar
  14. 14.
    Wagenlehner FM, Wydra S, Onda H, Kinzig-Schippers M, Sörgel F, Naber KG. Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother. 2003;47:3789–94.PubMedCrossRefGoogle Scholar
  15. 15.
    Isogai E, Isogai H, Hayashi S, Kubota T, Kimura K, Fujii N, Ohtani T, Sato K. Effect of antibiotics, levofloxacin and fosfomycin, on a mouse model with Escherichia coli O157 infection. Microbiol Immunol. 2000;44:89–95.PubMedGoogle Scholar
  16. 16.
    Shiomi M, Togawa M, Fujita K, Murata R. Effect of early oral fluoroquinolones in hemorrhagic colitis due to Escherichia coli O157:H7. Pediatr Int. 1999;41:228–32.PubMedCrossRefGoogle Scholar
  17. 17.
    Borgatta B, Kmet-Lunaček N, Rello J. E. coli O104:H4 outbreak and haemolytic-uraemic syndrome. Med Intensiva. 2012. doi: 10.1016/j.medin.2011.11.022.

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • H. F. Geerdes-Fenge
    • 1
  • M. Löbermann
    • 1
  • M. Nürnberg
    • 1
  • C. Fritzsche
    • 1
  • S. Koball
    • 2
  • J. Henschel
    • 3
  • R. Höhn
    • 4
  • H. C. Schober
    • 5
  • S. Mitzner
    • 2
  • A. Podbielski
    • 6
  • E. C. Reisinger
    • 1
  1. 1.Department of Medicine, Division of Tropical Medicine and Infectious Diseases, University Hospital RostockRostockGermany
  2. 2.Department of Medicine, Section of Nephrology, University Hospital RostockRostockGermany
  3. 3.Department of Medicine, Intensive Care Medicine, University Hospital RostockRostockGermany
  4. 4.Pediatric Department, University Hospital RostockRostockGermany
  5. 5.Department of MedicineKlinikum Südstadt RostockRostockGermany
  6. 6.Department of Clinical Microbiology and HygieneUniversity Hospital RostockRostockGermany

Personalised recommendations